

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

**SUPPLEMENTAL ANNOUNCEMENT
CONNECTED TRANSACTION IN RELATION TO REPURCHASE OF
EQUITY INTEREST IN A NON-WHOLLY-OWNED SUBSIDIARY**

Reference is made to the announcement of Shanghai INT Medical Instruments Co., Ltd.* 上海瑛泰醫療器械股份有限公司 (the “**Company**”) dated 23 February 2024 (the “**Announcement**”) in relation to the Repurchases. Unless otherwise defined, capitalized terms used in this announcement have the same meaning as those defined in the Announcement. The Board would like to provide the Shareholders and potential investors of the Company with further information of the Repurchases as follows:

1. Conditions Precedent

As disclosed in the Announcement, the Repurchases is subject to the conditions precedent of completion of the relevant registration procedures by the Target Company, including amending the Target Company’s articles of association, updating the Target Company’s register of members and completing the relevant registration procedures with the administration for market regulation in the PRC. It is expected that such conditions precedent will be fulfilled on or before 31 March 2024. The consideration payable to Huaige Int by the Company must be paid after but not before fulfilment of the aforementioned conditions precedent, and the Directors are of the view that the such payment term is in the interests of the Company and the Shareholders as a whole.

2. Consideration

The consideration for the Repurchases was determined after arm's length negotiation between the Company and the Sellers taking into account the financial position and future prospect of the Target Company and the actual amount of funds that the Sellers have invested into the Target Company.

3. Target Company

Huaige Int's original acquisition cost of the 3.8% equity interest in the Target Company is RMB38,000,000. The value of the 5.0% equity interest in the Target Company was RMB2,559,022.82 as of 31 December 2023. The financial information of the Target Company for the two years ended 31 December 2023, based on information available to the Company is set forth below:

	For the year ended 31 December 2022 (RMB) (audited)	For the year ended 31 December 2023 (RMB) (unaudited)
Net loss before taxation	(6,323,889.06)	(11,329,524.87)
Net loss after taxation	(6,323,889.06)	(11,329,524.87)

4. Huaige Health

Huaige Health is ultimately owned as to 82.5% by Mr. Wang Kai (王鐸) as its general partner and it has three individual limited partners which are independent third parties of the Company. Mr. Wang Kai (王鐸) is one of the Domestic Shareholders and personally holds approximately 3.26% equity interest of the Company.

Save as supplemented and disclosed above, the contents in the Announcement remain unchanged. This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
4 March 2024

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Mr. Zhang Weixin, Ms. Chen Hongqin, Dr. Song Yuan and Mr. Wang Ruiqin as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*